Cell and gene-based therapies and their potential to cure disease after a single course of therapy have revolutionized the way biopharmaceutical companies are addressing treatment. While the science behind them is revolutionary, their costs have raised concerns. How will state Medicaid agencies address the budgeting challenges that the new therapies pose? What do manufacturers, states, and patients need from CMS? Join this interactive panel for a look at the prospects and obstacles associated with these therapies, including what payment models will facilitate broader use of cell and gene therapies; how state Medicaid programs are addressing the challenges posed by these innovative yet costly therapies and, what potential actions the U.S. Centers for Medicare & Medicaid Services can take to encourage wider adoption.